🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07087093
Recruiting Not applicable

Effects of Ketone Esters on Circulating Senescent T Lymphocytes (T Cells) and Inflammation Levels in the Elderly

NCT07087093 · tracked via the Priya Life Science China tracker
Sponsor
First Affiliated Hospital of Harbin Medical University
Phase
Not applicable
Started
2025-01-07
Last updated
2025-07-25

Condition(s) studied

The Elderly

Investigational drug(s) / intervention(s)

Ketone ester

Ketone ester: KetoneAid Ke4 Pro Ketone Ester:20ml, tid po

Study summary

Studies have shown that aging can promote a variety of pathological processes, such as myocardial remodeling and cardiac dysfunction caused by ischemia-reperfusion injury and pressure load. Previous studies found that the level of circulating beta-hydroxybutyric acid decreased significantly with age. It has been reported that the ketogenic diet reduces the occurrence of tumors and neurodegenerative diseases in mice, improves motor coordination and endurance, and ultimately extends life span. Current research results have confirmed that ketone bodies have multiple mechanisms to exert beneficial effects on cardiovascular diseases. However, the effect of age-related cardiovascular disease has not been reported.

In order to further clarify the role of beta-hydroxybutyric acid in age-related cardiovascular diseases, find new intervention targets for elderly cardiovascular diseases, and develop new effective prevention and treatment measures for elderly cardiovascular diseases. We will further investigate this hypothesis by establishing a clinical cohort of the elderly population.

Eligibility

Sex
ALL
Min age
65 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Age: 65\~80 years old. 2. The subjects are in good health, and no history of chronic diseases. Exclusion Criteria: 1. Have used immunosuppressants or hormone drugs in the past six months. 2. There has been a significant change in diet within the past month. 3. Having digestive tract surgery within one year. 4. Severe liver dysfunction (alanine aminotransferase level \> 3.0 upper limit of normal). 5. Severe kidney dysfunction (creatinine clearance rate \< 30 mL/min). 6. History of malignant tumor.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
the First Affiliated Hospital, Harbin Medical University Harbin Heilongjiang Recruiting

More First Affiliated Hospital of Harbin Medical University trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07087093 on ClinicalTrials.gov ↗ ← All trials in China